Tegafur Gimeracil Oteracil

Warnings and Precautions:

• Use of Tegafur 15 mg + Gimeracil 4.35 mg + Oteracil 11.8 mg is restricted in patients with known Hypersensitivity to any of the active substances (tegafur, gimeracil, oteracil) or in patients with known history of severe/unexpected reactions to fluoropyrimidine therapy.
• Patients on Furmecil and with low white blood cell counts should be monitored precisely for infection and probability of other complications of neutropenia and treated as medically indicated (e.g., with antibiotics, granulocyte-colony stimulating factor [G-CSF].
• Administration of Furmecil 20 mg capsule in hepatitis B virus carriers, HBc antigen negative and HBc antibody positive patients, or HBs antibody positive and HBs antigen negative patients may result in reactivation of hepatitis B. Patients should be tested for HBV infection prior to initiating treatment with Furmecil.
• Patients taking treatment with Furmecil and with asthenia, anorexia, nausea, vomiting, stomatitis, diarrhoea, and gastrointestinal obstruction need to be monitored precisely for signs/symptoms of dehydration. Manage dehydration aggressively with rehydration and with other apt measures. 
• For detecting early changes in the renal function during treatment, renal parameters need to be precisely monitored (e.g., serum creatinine, CrCl). In case deterioration of glomerular filtration rate is noted,Furmecil 15 mg and/or cisplatin dose should be adjusted. 
• Concomitant use of Furmecil with Brivudine is not recommended. There must be at least a 4-week waiting period between end of therapy with brivudine and initiation of Furmecil therapy. The brivudine treatment can be started 24 hours after the last dose of Furmecil. 
• Furmecil treatment is not for patients with severe renal impairment because of the possibly higher incidence of adverse events of the lymphatic system and blood and the risk of unexpectedly higher exposure to 5-FU as a result of fluctuations in renal function in these patients, unless the benefits clearly outweigh the risks. 
• Prior to starting therapy with Furmecil, patients must tell their health specialist if they are pregnant, if they think they are pregnant, or if they intend to become pregnant. Do not take this medicinal product during pregnancy or breastfeeding.

Storage:

Store Tegafur Gimeracil Oteracil capsules at room temperature between 15°C and 25°C. Protect it from excess moisture and heat. Keep these capsules away from the reach of children.

Availability in India:

The Indian Pharma helps connect buyers with suppliers who can ship FURMECIL at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality and delivery for the FURMECIL Capsules.

Buying Procedure:

In order to buy FURMECIL, you can contact us at our Toll-free Number 1800 889 1064 or on WhatsApp Number +91 8130290915 or an Email to us at: info@theindianpharma.com along with your Identity Proof, Valid Prescription Letter and Medical Reports. 

Conclusion:

In conclusion, FURMECIL (Tegafur/Gimeracil/Oteracil), an anti-cancer medication has demonstrated high effectiveness with a favourable safety profile.